TABLE 3.
Details of convalescent plasma therapies at clinical trials.
| No. | Intervention/treatment | Study type/Phase | Primary purpose | Number of participants | Sponsors and Collaborators (ClinicalTrials.gov Identifier) |
| 1 | Convalescent Plasma | Interventional (Phase 1) | Treatment | 20 | Hospital San Jose Tec de Monterrey (NCT04333355) |
| 2 | Anti-SARS-CoV-2 convalescent plasma | Interventional (Early Phase 1) | Treatment | 20 | Orthosera Kft. (NCT04345679) |
| 3 | Convalescent Plasma Transfusion | Interventional (Phase 2) | Treatment | 20 | Institute of Liver and Biliary Sciences, India (NCT04346446) |
| 4 | Convalescent Plasma | Interventional (Phase 2) | Treatment | 15 | Saint Francis Care (NCT04343261 |
| 5 | COVID-19 convalescent plasma | Expanded Access | Treatment | Expanded Access | Mayo Clinic (NCT04338360) |
| 6 | Transfusion of COVID-19 convalescent plasma | Interventional (Phase 2) | Treatment | 120 | Assistance Publique - Hôpitaux de Paris (NCT04345991) |
| 7 | convalescent plasma from recovered COVID 19 donor | Interventional (Phase 2) | Treatment | 40 | King Fahad Specialist Hospital Dammam (NCT04347681) |
| 8 | Convalescent Plasma | Interventional (Phase 1/2) | Treatment | 500 | Stony Brook University (NCT04344535) |
| Standard Donor Plasma | |||||
| 9 | Convalescent Plasma | Interventional (Phase 2) | Treatment | 55 | Hackensack Meridian Health (NCT04343755) |
| 10 | Convalescent Plasma | Interventional (Phase 2) | Treatment | 426 | Erasmus Medical Center (NCT04342182) |
| 11 | Convalescent Plasma | Interventional (Phase 2) | Treatment | 278 | Cristina Avendaño Solá (NCT04345523) |
| 12 | Convalescent Plasma | Interventional (EarlyPhase1) | Treatment | 10 | University of Chicago (NCT04340050) |
| 13 | Plasma Hydroxychloroquine | Interventional (Phase 1/2) | Treatment | 80 | Universidad del Rosario (NCT04332835) |
| Azithromycin | |||||
| 14 | Convalescent Plasma | Interventional | Treatment | 30 | Mazandaran University of Medical Sciences (NCT04327349) |
| 15 | Convalescent Plasma | Observational | 15 | Shanghai Public Health Clinical Center (NCT04292340) | |
| 16 | Anti- SARS-CoV-2 Plasma SARS-CoV-2 non-immune Plasma | Interventional (Phase 2) | Treatment | 150 | Johns Hopkins University (NCT04323800) |
| 17 | Convalescent anti-SARS-CoV-2 plasma Sarilumab, Baricitinib, Hydroxychloroquine | Interventional (Phase 3) | Treatment | 1500 | Thomas Benfield (NCT04345289) |
| 18 | high-titer anti-Sars-CoV-2 plasma, oxygen therapy | Interventional (Phase 1) | Treatment | 115 | Baylor Research Institute (NCT04333251) |
| 19 | Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from a convalescent patient | Interventional | Treatment | 10 | A.O. Ospedale Papa Giovanni XXIII (NCT04346589 |